<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> is the predominant cause of morbidity in people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000822'>Hypertension</z:hpo> frequently coexists with <z:mp ids='MP_0002055'>diabetes</z:mp> and substantially increases the risk of developing end-organ damage </plain></SENT>
<SENT sid="2" pm="."><plain>Controlling <z:hpo ids='HP_0000822'>hypertension</z:hpo> in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> is therefore critical to reducing microvascular and macrovascular complications </plain></SENT>
<SENT sid="3" pm="."><plain>Agents that block the renin-angiotensin system are increasingly used in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> based on their cardiovascular and renoprotective effects, in addition to their direct effects on reducing blood pressure </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="9434">Telmisartan</z:chebi>, an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker (ARB), has a number of distinguishing pharmacological properties such as having the longest half-life and highest lipophilicity in its class </plain></SENT>
<SENT sid="5" pm="."><plain>The ONgoing <z:chebi fb="0" ids="9434">Telmisartan</z:chebi> Alone and in combination with <z:chebi fb="0" ids="8774">Ramipril</z:chebi> Global Endpoint Trial (ONTARGET(Â®)) trial showed that <z:chebi fb="0" ids="9434">telmisartan</z:chebi> reduces <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> (including <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and <z:hpo ids='HP_0001297'>stroke</z:hpo>) in subjects with a broad spectrum of <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>, including type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="9434">Telmisartan</z:chebi> is the only ARB indicated for the reduction of <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and end-organ damage, as well as in patients without <z:mp ids='MP_0002055'>diabetes</z:mp> but with a history of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, peripheral artery disease, or previous <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Trials of <z:chebi fb="0" ids="9434">telmisartan</z:chebi> in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and varying degrees of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> also suggest that this drug can slow the progression of <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e>, an effect that appears to be at least partly independent of reduction in blood pressure </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="9434">Telmisartan</z:chebi> is therefore an important therapeutic option for optimizing cardiovascular and renal protection in the type 2 diabetic population </plain></SENT>
</text></document>